Progesterone receptor status in determining the prognosis of estrogen receptor positive/HER2 negative breast carcinoma patients
dc.authorid | 0000-0002-6901-2646 | |
dc.authorid | 0000-0001-5279-0903 | |
dc.authorid | 0000-0001-9519-6373 | |
dc.authorid | 0000-0002-6839-2632 | |
dc.contributor.author | Bal, Öznur | |
dc.contributor.author | Arslan, Ülkü Yalçıntaş | |
dc.contributor.author | Durnalı, Ayşe | |
dc.contributor.author | Üyetrk, Ümmügül | |
dc.contributor.author | Demirci, Ayşe | |
dc.date.accessioned | 2021-06-23T19:42:34Z | |
dc.date.available | 2021-06-23T19:42:34Z | |
dc.date.issued | 2015 | |
dc.department | BAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü | en_US |
dc.description.abstract | Purpose: To evaluate the impact of progesterone receptor (PR) status on estrogen receptor (ER)-positive and HER2-negative breast cancer. Methods: A total of 1673 operable breast cancer patients, diagnosed from June 1984 to June 2011 were retrospectively reviewed and 400 patients with ER-positive and HER2-negative tumors were identified and evaluated. ER-positive and HER2-negative patients were classified into two groups: group A: ER+/PR-/HER2- and group B: ER+/PR+/HER2- according to PR status. Results: Median follow-up was 14.2 years (range 10.1-18.2). The ratio of postmenopausal patients was significantly higher in group A (68.2%, p=0.015). Grade 1 tumor and stage I disease were significantly higher in group B (15%, p=0.007 and 15%, p=0.005, respectively). Mean overall survival (OS) and disease free survival (DFS) were significantly better in group B (15.3 +/- 1.5 years vs 8.7 +/- 0.8 years, p=0.032; 10.5 +/- 1.6 years vs 5.7 +/- 0.5 years, p=0.022) as compared with group A. Relative risk for recurrence and death were two-fold higher in group A (p=0.05 and p=0.01, respectively). Conclusion: PR status exerts a significant impact on prognosis of ER+/HER2- breast cancer. | en_US |
dc.identifier.endpage | 34 | en_US |
dc.identifier.issn | 1107-0625 | |
dc.identifier.issn | 2241-6293 | |
dc.identifier.issue | 1 | en_US |
dc.identifier.pmid | 25778292 | en_US |
dc.identifier.scopusquality | Q3 | en_US |
dc.identifier.startpage | 28 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12491/8536 | |
dc.identifier.uri | https://www.webofscience.com/wos/woscc/full-record/WOS:000351566500004 | |
dc.identifier.volume | 20 | en_US |
dc.identifier.wos | WOS:000351566500004 | en_US |
dc.identifier.wosquality | Q4 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.institutionauthor | Üyetrk, Ümmügül | |
dc.language.iso | en | en_US |
dc.publisher | Imprimatur Publications | en_US |
dc.relation.ispartof | Journal Of Buon | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Breast Cancer | en_US |
dc.subject | Estrogen Receptor | en_US |
dc.subject | HER2 | en_US |
dc.subject | Progesterone Receptor | en_US |
dc.subject | Prognosis | en_US |
dc.title | Progesterone receptor status in determining the prognosis of estrogen receptor positive/HER2 negative breast carcinoma patients | en_US |
dc.type | Article | en_US |
Dosyalar
Orijinal paket
1 - 1 / 1
Küçük Resim Yok
- İsim:
- oznur-bal.pdf
- Boyut:
- 467.94 KB
- Biçim:
- Adobe Portable Document Format
- Açıklama:
- Tam Metin/Full Text